Correlation Between Esperion Therapeutics and Mesoblast
Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Mesoblast at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Mesoblast into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Esperion Therapeutics and Mesoblast, you can compare the effects of market volatilities on Esperion Therapeutics and Mesoblast and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Mesoblast. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Mesoblast.
Diversification Opportunities for Esperion Therapeutics and Mesoblast
0.57 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Esperion and Mesoblast is 0.57. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Mesoblast in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mesoblast and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Mesoblast. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mesoblast has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Mesoblast go up and down completely randomly.
Pair Corralation between Esperion Therapeutics and Mesoblast
Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 0.97 times more return on investment than Mesoblast. However, Esperion Therapeutics is 1.03 times less risky than Mesoblast. It trades about -0.14 of its potential returns per unit of risk. Mesoblast is currently generating about -0.23 per unit of risk. If you would invest 215.00 in Esperion Therapeutics on December 30, 2024 and sell it today you would lose (65.00) from holding Esperion Therapeutics or give up 30.23% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 96.77% |
Values | Daily Returns |
Esperion Therapeutics vs. Mesoblast
Performance |
Timeline |
Esperion Therapeutics |
Mesoblast |
Esperion Therapeutics and Mesoblast Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Esperion Therapeutics and Mesoblast
The main advantage of trading using opposite Esperion Therapeutics and Mesoblast positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Mesoblast can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will offset losses from the drop in Mesoblast's long position.Esperion Therapeutics vs. Elanco Animal Health | Esperion Therapeutics vs. SIGA Technologies | Esperion Therapeutics vs. ANI Pharmaceuticals | Esperion Therapeutics vs. Phibro Animal Health |
Mesoblast vs. Aditxt Inc | Mesoblast vs. Lipocine | Mesoblast vs. Connect Biopharma Holdings | Mesoblast vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |